

## Smoking & Atherosclerosis

### Non-cardiac Biomarkers

- Carotid Artery Disease

- \* Intimal-medial wall thickness (*Ultrasound*)
- \* Arterial-luminal narrowing (*Doppler Velocities*)

- Peripheral Vascular Disease

- \* Ankle/Brachial Index (*ABI*)
- ABI = systolic BP in leg ÷ systolic BP in arm
- \* Severity of Claudication (*Exercise time & distance*)

---

---

---

---

---

---


---

---

## Smoking & Carotid Artery Atherosclerosis

### Independent Risk Factors of Increased Wall Thickness

- Pack-years ( $p < 0.0005$ )
- Age ( $p < 0.0001$ )
- HTN ( $p < 0.004$ )



Dempsey et al. *Stroke* 1992

---

---

---

---

---

---

---

---


## Progression of Carotid Disease

### The Atherosclerosis Risk in Communities (ARIC) Study

### Smoking & 3-year progression

- Continual smoking-50%
- Environmental tobacco-25%

n=10,914



Howard et al. *JAMA* 1998

---

---

---

---

---

---

---


---

## Smoking & Peripheral Vascular Disease

Ankle/brachial Index (ABI)  
Acute Smoking decreased ABI  
in chronic smokers with  
claudication

n=10

Yataco et al. *Angiology* 1999




## Smoking Status & Functional Limitation

### Walk Distance in 6 minutes

Among patients with  
claudication and similar levels of  
calf blood flow, non-smokers  
walk further than former  
smokers who in turn, walk  
further than persistent smokers.

n=415

Cahan et al. *Angiology* 1999



## Subjective Biomarkers *Estimates of 'Quality of Life'*

- Short Form 36 Item Health Survey (SF-36)
  - \* 36 questions used as Medical Outcomes Data
  - \* Includes 8 domains (physical functioning, role functioning, social functioning, mental health, pain, emotional, energy/fatigue & general health)
  - \* Accepted, reliable and previously validated
- Sickness Impact Profile (SIP)
  - \* 146 questions to establish 14 subscales
  - \* More cumbersome and less sensitive than SF-36
- Seattle Angina Questionnaire

### Biomarkers for Studies on Smoking

#### Summary

- 'Macro' biomarkers are relevant but impractical
  - \* Death, MI, Stroke, Loss of limb require large # of subjects
- Biomarkers of myocardial ischemia are practical
  - \* EKG is inexpensive but ? accuracy
  - \* Nuclear imaging (SPECT & PET) is sensitive but ? cost
  - \* 2D ECHO/Doppler is available but ? reproducibility
  - \* Fast CT Scan & MRI needs further validation and ? cost
- Biomarkers of cerebral & peripheral atherosclerosis
  - \* Ultrasound/Doppler of carotids is feasible but ? reproducibility
  - \* ABIs and exercise testing for claudication but ? sensitivity

---

---

---

---

---

---

---

### Selection of the optimal biomarker for any study involving smoking



- Cost of the project
- Hypothesis of the project
- Clinical relevance of the marker
- Availability of the marker
- Predictive accuracy of the marker
- Reproducibility of the marker

---

---

---

---

---

---

---

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Source: <https://www.industrydocuments.ucsf.edu/docs/nhmj0001>